TECENTRIQ 1 875 mg, solution for injection bottle, 15 ml
Active ingredients: ATÉZOLIZUMAB
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Solution for injectionbottle, 15 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TECENTRIQ 1 875 mg, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon(s) en verre de 15 ml
- Marketing authorisation holder
- ROCHE REGISTRATION (ALLEMAGNE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 28 Oct 2024
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69209340CIP75510014CIP133400955100140Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ATÉZOLIZUMABsolution | 1 875 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.